HEAL Initiative: Whole Joint Health Program (R61/R33 Clinical Trial Required)
NIH supports phased clinical research lasting up to five years to identify mechanisms driving joint pain and test non-pharmacologic or multimodal interventions targeting them.
Funder: National Institutes of Health
Due Dates: October 30, 2026 (Application, 5:00 PM applicant organization’s local time)
Funding Amounts: Recommended annual direct costs: R61 $500,000; R33 $700,000–$800,000 depending on phase length; up to 5 years total
Summary: Supports phased clinical research identifying multi-tissue mechanisms of joint pain and testing interventions that directly target those mechanisms.
Key Information: Mechanistic clinical trials are required; studies assessing clinical efficacy or effectiveness will not be reviewed.
Description
The NIH Helping to End Addiction Long-term (HEAL) Initiative supports hypothesis-driven research on understudied biological mechanisms driving joint pain. Led by the National Center for Complementary and Integrative Health (NCCIH), this R61/R33 program treats the whole joint as an integrated system encompassing articular tissues, periarticular tissues, and peripheral physiological or neural systems. Its goal is to advance safe, non-addictive, prevention-oriented approaches to chronic pain.
The R61 phase identifies and validates mechanisms distinguishing clinical joint pain from healthy joint function. The R33 phase then tests how non-pharmacologic or multimodal interventions modify those mechanisms. Relevant approaches include imaging, biomarker profiling, neuromuscular assessment, and measures of inter-tissue communication. Interventions may include manual therapies, exercise, thermotherapies, acupuncture, targeted injections, neuromodulation, or justified multimodal combinations.
